Abstract: The present invention relates to a novel oral pharmaceutical composition of micronized megestrol acetate at a concentration of 15 to 150 mg/mL comprising polysorbate at a concentration of 0.005% to 0.015% weight/volume and polyethylene glycol at a concentration of 5-30% weight/volume which composition forms a stable flocculated suspension in water. The invention further comprises the micronized megestrol acetate formulation described above with added preservatives, buffers, sweeteners and flavoring agents.

Abstract: Mania is treated by administering, to a patient in need thereof, galanthamine or a salt or derivative thereof or a functional equivalent of galanthamine, the functional equivalent being an acetylcholinesterase inhibitor which is active substantially selectively at nicotinic receptor sites.

Abstract: The present invention relates to compositions and methods for inhibiting protein aging. Accordingly, a composition is disclosed which comprises an agent or compound capable of inhibiting the formation of advanced glycosylation end products of target proteins by reacting with the carbonyl moiety of the early glycosylation product of such target proteins formed by their initial glycosylation. Suitable agents are amino acids and their derivatives which contain an active nitrogen-containing group. Particular agents comprise lysine and mixtures thereof. The method comprises contacting the target protein with the composition. Both industrial and therapeutic applications for the invention are envisioned, as food spoilage and animal protein aging can be treated.

Abstract: A method for treatment of ulcerative colitis (and sequelae to surgically treated colitis, for instance ileal pouchiris) and ulcerative proctitis comprising administration to a patient suffering therefrom of a therapeutically effective amount of a local anaesthetic or a pharmaceutically acceptable salt thereof, preferably lidocaine hydrochloride in the form of a pharmaceutically acceptable preparation.

Abstract: A medicament for the topical treatment of burned, irritated, ulcered, chafed, or infected, skin, a method of making the medicament, and a method of use of the medicament, the medicament comprising: about 70.6% by weight of Petrolatum U.S.P.(Vaseline); about 6.8% by weight of Wool Fat U.S.P.; about 4.0% by weight of a Sulfa compounded-ingredient; about 17.4% by weight of Zinc Oxide U.S.P.; and about 1.2% by weight of Disodium Formad Dehyde Sulfoxylate Diamino Diphenyl Sulfone.

Abstract: A method of treating a mammal comprises administering to a mammal an effective amount to provide a reduction inflammation in the mammal of a compound selected from the group consisting of those having the formula: ##STR1## pharmaceutically acceptable acid addition salts thereof and mixtures thereof, wherein R.sub.1 and R.sub.4 are independently selected from the group consisting of H and alkyl radicals having 1 to 4 carbon atoms; the R.sub.2 s are independently selected from H or alkyl radicals having 1 to 4 carbon atoms or are, together, oxo; the R.sub.3 s are independently selected from H or alkyl radicals having 1 to 4 carbon atoms or are, together, oxo; the 2-imidazolin-2-ylamino group may be in any of the 5-, 6, 7- or 8- positions of the quinoxaline nucleus; and R.sub.5, R.sub.6 and R.sub.7 each is located in one of the remaining 5-, 6-, 7- or 8- positions of the quinoxaline nucleus and is independently selected from the group consisting of Cl, Br, H and alkyl radicals having 1 to 3 carbon atoms.

Abstract: The present invention relates to compositions and methods for inhibiting nonenzymatic cross-linking (protein aging). Accordingly, composition is disclosed which comprises 1,2-disubstituted benzimidazoles capable of inhibiting the formation of advanced glycosylation endproducts of target proteins by reacting with the carbonyl moiety of the early glycosylation product of such target proteins formed by their initial glycosylation. The method comprises contacting the target protein with the composition. Both industrial and therapeutic applications for the invention are envisioned, as food spoilage and animal protein aging can be treated.

Abstract: The invention concerns thiosulphinic acid derivatives, medicaments containing these compounds and their use in medicine. It has been found that thiosulphinic acid derivatives display outstanding inflammation-inhibiting properties. The compounds prove to be especially advantageous in the treatment of PAF-induced inflammatory processes of the bronchial area.

Abstract: The present invention relates to compositions and methods for inhibiting nonenzymatic cross-linking (protein aging). Accordingly, a composition is disclosed which comprises substituted 1,2,4-triazoles capable of inhibiting the formation of advanced glycosylation endproducts of target proteins by reacting with the carbonyl moiety of the early glycosylation product of such target proteins formed by their initial glycosylation. The method comprises contacting the target protein with the composition. Both industrial and therapeutic applications for the invention are envisioned, as food spoilage and animal protein aging can be treated.

Abstract: Unnatural dipeptoids of .alpha.-substituted Try-Phe derivatives are useful as agents in the treatment of panic disorders. These dipeptoids are Cholecystokinin-B Receptor (CCK.sub.B) antagonists having utility in the prevention of panic attacks in patients prone to these attacks.

Abstract: This invention relates to a method of lowering abnormally high serum cholesterol levels in the body without significantly reducing mevalonic metabolite synthesis and to novel pharmacological compositions containing as an active ingredient bisphosphonic acid and ester compounds containing a mono-, bi- or tricyclic ring linked with a bisphosphonate moiety through a basic amino alkylene group. This invention also provides novel bisphosphonate compounds and the processes for their preparation.

Abstract: Cholesterol lowering compounds and compositions are formed from the photochemical treatment of the Zaragozic Acids followed by esterification. These compounds and compositions are active squalene synthetase inhibitors useful in the treatment of hypercholesterolemia.

Abstract: Vaginal pharmaceutical compositions administrable through the topical route, particularly in the form of vaginal foams and creams containing a therapeutically effective amount of rifaximin (Common International Denomination) are useful in the treatment of vaginal infections, particularly bacterial vaginosis.

Abstract: The invention concerns pharmaceutical compositions comprising clozapine and a radical scavenger.

Abstract: A therapeutic agent used for photodynamic therapy of atherosclerosis of mammals, which agent comprises at least one member of fluorescent compounds selected from the group consisting of tetrapyrrole carboxylic acids having at least one carboxyl group, corresponding di- or tetrahydrotetrapyrrole carboxylic acids, and mono-, di- or polyamides of the tetrapyrrole carboxylic acids with amino-mono- or dicarboxylic acids and their salts.

Abstract: The present invention relates to a method of effecting immunosuppression in a patient in need thereof comprising administering to said patient an effective immunosuppressive amount of certain 5'-amine substituted adenosine analogs.

Abstract: A pharmaceutical composition useful for lowering blood sugar and suppressing appetite in mammals. The composition comprises compounds of a formula selected from VOL.sub.2 or VO(OR)L.sub.2 in which L is a bidentate monoprotic ligand and R is an organic group. The composition includes a pharmaceutically acceptable carrier. The invention also provides a method of lowering blood sugar and suppressing appetite in a mammal that comprises administering to the mammal a compound of the above formula.

Abstract: An euthanasia solution based upon gamma-hydroxybutramide, a cardiotoxic amount of a compound selected from a chloroquine and quinacrine compound and lidocaine as a base or as a water soluble salt is described. The composition provides effective euthanasia without unwanted side effects, particularly in dogs, cats and horses. In addition, it does not contain substances controlled by the Federal Drug Control Administration.

Abstract: An euthanasia solution based upon gamma-hydroxybutramide and a cardiotoxic amount of a compound selected from chloroquine and quinacrine is described. The composition provides effective euthanasia without unwanted side effects.

Abstract: Provided are methods of treating inflammation, arthritis and muscular dystrophy and preventing ischemia-induced cell damage employing certain phenol and benzamide compounds.